Professional Documents
Culture Documents
Chylomicrons
VLDL
Distinguished by size
and density
Each contains
different kinds and
amounts of lipids
and proteins
Class
Size (nm)
Lipids
Major
Apoproteins
Chylomicra
100-500
Dietary TG
B-48,C-II,E
VLDL
30-80
Endogenous
TG
B-100,C-II,E
IDL
25-50
B-100, E
LDL
18-28
CEs
B-100
HDL
5-15
CEs
A,C-II,E
Lp (a)
25-30
CEs
B-100 &
glycoproteins
Chylomicro
n
VLDL
IDL
Cholesterol
22
35
47
19
Triglyceride
82
52
20
Phospholipi
d
18
20
23
28
Lipid
LDL HDL
Chylomicron
remnants
Liver
Synthesizes & metabolizes lipids
Central command center for relation of lipid
metabolism
Makes additional lipoproteins
Transports exogeneous ( dietary ) triglycerides
90 - 95 % by weight is triglycerides(dominant)
Absent from fasting plasma
Removed from the plasma within 6 hours by the
liver
Inadequate clearance produces a creamy layer on
the plasma
12
13
Cholest
AA
FA
P,
glycerol
Vessel
wall
Dietary
cholesterol
Exogenous
Intestine
(~300700 mg/day)
Biliary
cholesterol
Fecal bile
acids
and neutral
sterols
~700 mg/day
(~1000 mg/day)
Liver
Synthesis
(~800 mg/day)
Extrahepatic
tissues
Endogenous
Adapted from Champe PC, Harvey RA. Biochemistry. 2nd ed. Philadelphia: Lippincott Raven, 1994; Glew
RH. In Textbook of Biochemistry with Clinical Correlations. 5th ed. New York: Wiley-Liss, 2002:728-777;
Ginsberg HN, Goldberg IJ. In Harrisons Principles of Internal Medicine. 14th ed. New York: McGraw-Hill,
1998:2138-2149; Shepherd J Eur Heart J Suppl 2001;3(suppl E):E2-E5; Hopfer U. In Textbook of
Biochemistry with Clinical Correlations. 5th ed. New York: Wiley-Liss, 2002:1082-1150.
1000 mg
Inhibitors
Resins
Plant stanols
NPC1L1
(Ezetimibe)
Exogeneous Pathway
Transport of dietary lipids, mostly the chylomicrons
transportation of triglycerides to the liver
Endogeneous Pathway
Transportation of lipids from the liver to the tissues
( VLDL & LDL )
Effects of hormones
Insulin
Remember, insulin always decreases plasma glucose
Inactivates lipase decreases lipolysis and the catabolism of
triglycerides to fatty acids / glucose
Stimulates lipogenesis ( fatty acid conversion to triglycerides )
Insulin helps make fat
In diabetes mellitus, insulin deficiency promotes the release of fatty
acids and their conversion to triglycerides by the liver
20
Made by liver
Transports endogeneous triglycerides from
liver to tissues
50 - 65 % by weight is triglycerides
Excess dietary carbohydrates are converted
to triglycerides by the liver
1- Assembly and
secretion
2- Hydrolysis by LPL
3- Direct uptake by
hepatocyte
4- Flux of pathway
into LDL
3
1
2
4
Cell membranes
Hormone production
Protein (21%)
ApoB-100
Binds to specific LDL receptor
LDL receptors
Increase
LDL
SFAs
Trans fatty acids
High cholesterol
intake
Lifestyle factors
Genetics
Decrease
LDL
High PUFA diet
-3 fatty acids
Dietary fiber
Lifestyle
factors
Genetics
Insulin resistance
increased NEFA
and glucose flux to
liver
Increased
VLDL
IR impairs
LDLR
Insulin
resistance and
decreased apoB degradation
Insulin
resistance
and
decreased
LPL
FCHL
DM II
Metabolic
syndrome
Direct Association
Indirect
Association
Inverse
relationship
with HDL
Marker for
atherogenic TG
remnant
accumulation
Insulin
resistance
33
Antiinflammatory
Anti-thrombotic
Modulation of
endothelial function
HDL-C
Cholesterol
acceptor
Cholesterylester
donor
Reverse
Cholesterol
Transport (RCT)
Elevated triglycerides
Post-prandial lipemia
Small dense LDL (type
B)
Elevated LDL
Low HDL cholesterol
Elevated Total
Cholesterol
Fat Cells
Liver
FFA
IR
Insulin
CE
TG
VLDL (CETP) HDL
(hepatic lipase)
Apo B
TG
VLDL
Apo A-1
CE (CETP) TG
LDL
SD
LDL
(lipoprotein
or
hepatic lipase)
Kidney
Increased
Apo B
Triglyceride
s
VLDL
LDL and
Small Dense
LDL
Decreased
HDL
Apo A-I
Low HDL-cholesterol
Increased catabolism of small dense
HDL
Low HDL cholesterol by both content
and # particles
CETP
inhibitors
High triglycerides
Post-prandial
lipemia
Small dense LDL
(type B)
Low HDL
cholesterol
Fibrate
Niacin
Statin
CETP
ABCA-1
VLDL : Triglycerides/ 5
Fredrickson-Levy-Lees Classification
Type
Lipoprotein Elevation
Chylomicrons
IIa
LDL
IIb
LDL + VLDL
III
IDL (LDL1)
IV
VLDL
VLDL + Chylomicrons
IDL, intermediate-density lipoprotein
LDL, low-density lipoprotein
VLDL, very-low-density lipoprotein
DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM: Pharmacotherapy: A Pathophysiologic Approach, 7th50
Edition: http://www.accesspharmacy.com
Lipid Phenotype
Plasma Lipid
Phenoty
Levels [mmol/L
Lipoprotein pe
(mg/dL)]
Elevated
Isolated hypercholesterolemia
Familial
Heterozygotes TC = LDL
IIa
hypercholesterolem 713 (275500)
ia
Clinical Signs
Homozygotes TC
>13 (>500)
LDL
IIa
Usually develop
xanthomas in adulthood
and vascular disease in
childhood
Familial defective
Apo B-100
Heterozygotes TC = LDL
713 (275500)
IIa
IIa
Usually asymptomatic
until vascular disease
develops; no xanthomas
IV
Asymptomatic; may be
associated with
increased risk of
vascular disease
Polygenic
TC = 6.59 (250
hypercholesterolem 350)
ia
LDL
Isolated hypertriglyceridemia
Familial
TG= 2.88.5 (250 VLDL
hypertriglyceridemi 750)
a
Familial LPL
deficiency
TG>8.5 (750)
May be asymptomatic;
may be associated with
pancreatitis, abdominal
pain,
DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM: Pharmacotherapy: A Pathophysiologic
Approach, 7th51
hepatosplenomegaly
Edition: http://www.accesspharmacy.com
Chylomicron I, V
s, VLDL
Usually develop
xanthomas in adulthood
and vascular disease at
3050 years
Lipid
Phenotype
Dysbetalipoproteinemia
VLDL, IDL;
LDL normal
III
Usually
asymptomatic until
vascular disease
develops; familial
form may present as
isolated high TG or
isolated high LDL
cholesterol
Usually
asymptomatic until
vascular disease
develops; may have
palmar or
tuboeruptive
xanthomas
DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM: Pharmacotherapy: A Pathophysiologic Approach, 7th52
Edition: http://www.accesspharmacy.com
53 53
Age
Men: 45 years
Women: 55 years or premature menopause without estrogen replacement
therapy
Family history of premature CHD (definite myocardial infarction or sudden
death before age 55 years in father or other male first-degree relative, or
before age 65 years in mother or other female first-degree relative)
Cigarette smoking
Hypertension (140/90 mm Hg or taking antihypertensive medication)
Low HDL cholesterol (<40 mg/dL)b
DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM: Pharmacotherapy: A Pathophysiologic Approach, 7th58
Edition: http://www.accesspharmacy.com
Athrogenesis
L-Selectin,
Integrins
VCAMLDLE-Selectin,
1,
P-Selectin
ICAM-1
Monocyt
e
MCP-1
OxLDL
Intima
M-CSF
Other
inflammato
ry triggers
Macrophage
Activation &
Division
Media
Libby et al. Circulation 2002;105:1135-1143.
Proinflammatory
Risk Factors
Primary Pro-inflamatory Cytokines
(eg, IL-1, TNF-)
ICAM-1
Selectins, HSPs,
etc.
Endothelium
and other
cells
IL-6
Messenger
Cytokine
CRP
SAA
Liver
Circulation
HSPs=heat shock proteins; SAA=serum amyloid-A.
Adapted from Libby and Ridker. Circulation. 1999;100:1148-1150.
Total
Normal
Physical
inactivity
Excessive
food intake
Stress
Smoking
Obesity
Hypertension
Risk factor
modificatio
n
Diabetes
Dyslipidaemia
Atherosclerosis
Chronic
heart failure
Atherosclerosis
Arrhythmia
At least 3 of
Abdominal obesity: waist circumference > 102 cm (M)
> 88 cm (F)
Hypertriglyceridemia
Central
obesity
Insulin
Resistanc
e
Type 2
Diabetes
Dyslipidemi
a
Hypertensio
n
Environmental factor
Genetic variation
Abdominal
Adipokines obesity
Adipocyte
Cytokines
Monocyte/
macrophag
Inflammatory markers
Insulin resistance
Tg
Metabolic syndrome
HDL
BP
Atherosclerosis
Plaque rupture/thrombosis
Cardiovascular events
Treatment
NCEP ATP-III guidelines
Modification of lipids and major risk factors
See Table 15.9
Medications
See Table 15.10
Procedures
Angioplasty
CABG
Nutrition Therapy
Therapeutic Lifestyle Changes (TLC) developed
as component of ATP-III
Nutrient Intake
Recommended
Coronary
Angioplasty
Coronary Bypass
Surgery (CABG)